Human Surfactant from Amniotic Fluid in the Treatment of Respiratory Distress Syndrome

  • M. Hallman
  • M. Pohjavuori
  • K. Bry
  • T. A. Merritt
Conference paper


The major issue in surfactant substitution has been the availability of an efficient and safe preparate. At present the quantitative and especially the qualitative requirements of surfactant are unclear. The evaluation is complex because the severity of RDS varies widely. There are a number of possible preparates that function well both in vitro and in vivo in animals. The first and the best known was that used by Fujiwara et al. (1980). However, the suitability is ultimately evaluated on the basis of controlled trials comparing the outcome and the long-term follow-up.


Amniotic Fluid Patent Ductus Arteriosus Hyaline Membrane Disease Natural Surfactant Exogenous Surfactant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Enhörning G, Grossman G, Robertson B (1973) Tracheal deposition of surfactant before the first breath. Am Rev Respir Dis 107: 921–926PubMedGoogle Scholar
  2. Friedman WF, George BC (1984) Treatment of congestive heart failure by altering loading conditions of the heart. J Pediatr 106: 697–706Google Scholar
  3. Fujiwara T, Chida S, Watabe Y, Maeta H, Morita T, Abe T (1980) Artificial surfactant therapy in hyaline membrane disease. Lancet 1: 55–59PubMedCrossRefGoogle Scholar
  4. Hallman M (1984) Antenatal diagnosis of lung maturity. In: Robertson B, Van Golde LMG, Batenburg JJ (eds) Pulmonary surfactant. Elsevier, Amsterdam, pp 419–448Google Scholar
  5. Hallman M, Gluck L (1982) Respiratory distress syndrome — update 1982. Pediatr Clin North Am 29: 1057–1075PubMedGoogle Scholar
  6. Hallman M, Merritt TA, Schneider H, Epstein BL, Mannino F, Edwards DK, Gluck L (1983) Isolation of human surfactant from amniotic fluid and a pilot study of its efficacy in respiratory distress syndrome. Pediatrics 71: 473–482PubMedGoogle Scholar
  7. Hallman M, Merritt TA, Järvenpää A-L, Boynton B, Mannino F, Gluck L, Moore T, Edwards D (1985): Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial. J Pediatr 106: 963–969PubMedCrossRefGoogle Scholar
  8. Merritt TA, Hallman M, Bloom B et al. (1986) Prophylactic treatment of very premature infants with human surfactant. N Engl J Med 315: 785–790PubMedCrossRefGoogle Scholar
  9. Pinkerton KE, Barry BE, O’Neil JJ, Raub JA, Pratt PC, Crapo JD (1982) Morphologic changes in the lung during the lifespan of Fischer 344 Rats. Am J Anat 164: 155–174PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • M. Hallman
  • M. Pohjavuori
  • K. Bry
  • T. A. Merritt

There are no affiliations available

Personalised recommendations